The Role of Atypical Antipsychotics in Inadequate‐response and Treatment‐resistant Depression

Kasper, Siegfried; Akimova, Elena; Montgomery, Stuart

doi:10.1002/9781118556719.ch5

Cited by 3 publications

(1 citation statement)

References 47 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adding an atypical antipsychotic to antidepressant treatment is common in the treatment of depression [24,25]. In treatment-resistant or severe cases of depression, the antipsychotic combination is the preferred method [26,27]. Psychotic and anxiety symptoms improved more in patients treated with atypical antipsychotics than in patients treated with antidepressant monotherapy, and this was consistent with other studies [28,29].…”

Section: Discussionsupporting

confidence: 66%

The relationship between remission, non-specific structural cerebral pathologies, and atypical antipsychotic combination treatment in patients hospitalized with depression: a cross-sectional study

Uğurlu

Çayköylü

2017

Psychiatry and Clinical Psychopharmacology

View full text Add to dashboard Cite

OBJECTIVE: The aim of this study was to determine the relationship between clinical variables related to patients hospitalized with depression. METHODS: The files of patients hospitalized with depression were examined. Sociodemographic characteristics, clinical features and imaging reports were considered. Data for statistical analysis was obtained only from files that provided clear information. RESULTS: The appropriate treatment for anxiety and psychotic symptoms had a significant effect on response in depression. The presence of non-specific structural cerebral pathologies had an important relationship with the length of hospitalization and suicidal ideation. CONCLUSIONS: Depression is a disorder of which cause, course and outcome has been determined by several different factors. Therefore, addressing depression in a holistic manner is extremely important.

show abstract

Section: Discussionsupporting

confidence: 66%

The relationship between remission, non-specific structural cerebral pathologies, and atypical antipsychotic combination treatment in patients hospitalized with depression: a cross-sectional study

Uğurlu

Çayköylü

2017

Psychiatry and Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

Evidence-based pharmacotherapy of treatment-resistant unipolar depression

Dold

Kasper

2016

International Journal of Psychiatry in Clinical Practice

View full text Add to dashboard Cite

Treatment resistance to the antidepressive pharmacotherapy represents one of the most important clinical challenges in the pharmacological management of unipolar depression. In this review, we aimed to summarise the evidence for various pharmacological treatment options in therapy-resistant unipolar depression derived from clinical trials, systematic reviews, meta-analyses and treatment guidelines. The first measure in case of insufficient response to the initial antidepressant monotherapy contains the debarment of 'pseudo-resistance', potentially caused by inadequate dose and treatment duration of the antidepressant, insufficient plasma levels, non-compliance of the patient regarding medication intake or relevant psychiatric and/or somatic comorbidities. Applying a dose escalation of the current antidepressant cannot be generally recommended as evidence-based treatment option and the efficacy depends on the class of antidepressants. There is no compelling evidence for a switch to another, new antidepressant compound after insufficient response to a previous antidepressant. The combination of two antidepressants should be preferentially established with antidepressants characterised by different mechanisms of action (e.g. reuptake inhibitors together with presynaptic autoreceptor inhibitors). At present, the most convincing body of evidence exists for the augmentation of antidepressants with second-generation antipsychotic drugs and lithium. Hence, both strategies are consistently advised by treatment guidelines as pharmacological first-line strategy in treatment-resistant depression.

show abstract

New possibilities for potentiating the effects of antidepressants of the group of selective serotonin reuptake inhibitors by the regulatory peptide Selank in the treatment of anxiety and depressive disorders

Вербенко¹,

Shakina²

2019

Vrach

View full text Add to dashboard Cite

The Role of Atypical Antipsychotics in Inadequate‐response and Treatment‐resistant Depression

Cited by 3 publications

References 47 publications

The relationship between remission, non-specific structural cerebral pathologies, and atypical antipsychotic combination treatment in patients hospitalized with depression: a cross-sectional study

The relationship between remission, non-specific structural cerebral pathologies, and atypical antipsychotic combination treatment in patients hospitalized with depression: a cross-sectional study

Evidence-based pharmacotherapy of treatment-resistant unipolar depression

New possibilities for potentiating the effects of antidepressants of the group of selective serotonin reuptake inhibitors by the regulatory peptide Selank in the treatment of anxiety and depressive disorders

Contact Info

Product

Resources

About